Margaret Tempero, MD

Gastrointestinal oncologist

Dr. Margaret Tempero is director of the UCSF Pancreas Center and leader of the Pancreas Cancer Program at the UCSF Helen Diller Family Comprehensive Cancer Center. She is a pioneer in applying radioactively tagged antibodies for cancer therapy and has led national research projects for gastrointestinal cancer, including pancreatic cancer.

Tempero has held editorial positions on prestigious journals such as Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research and American Journal of Medicine. She is a professor of medicine in Hematology and Oncology and is the Rombauer Family Distinguished Professor in Pancreas Cancer Clinical and Translational Science. Prior to joining UCSF Medical Center, she was deputy director of the Cancer Center at the University of Nebraska.


Gastrointestinal Medical Oncology Clinic
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-9888
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. – 5 p.m.

Pancreas Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Patient Information and Appointments: (415) 353-9888
Administrative Inquiries: (415) 476-3270
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. — 5 p.m.

Conditions & Treatments

More about Margaret Tempero


University of Nebraska School of Medicine 1977


University of Nebraska Medical Center, Internal Medicine 1980


Memorial Sloan-Kettering Cancer, Hematology 1981
University of Nebraska Medical Center, Oncology 1983

Selected Research and Publications

  1. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 Sep 21.
  2. Tempero M. Your Genes: Getting the Best Fit. J Natl Compr Canc Netw. 2017 Sep; 15(9):1083.
  3. Tempero M. When It's Really Good, We Know It! J Natl Compr Canc Netw. 2017 Aug; 15(8):973.
  4. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Aug; 15(8):1028-1061.
  5. Tempero M. Reducing the Cost of Cancer Care: When Less Is More. J Natl Compr Canc Netw. 2017 Jul; 15(7):853.
  6. Tempero M. Getting Practical About Recertification. J Natl Compr Canc Netw. 2017 Jun; 15(6):753.
  7. Tempero M. Hospice: Angels at Work. J Natl Compr Canc Netw. 2017 May; 15(5):549.
  8. Tempero M. Active Systemic Treatment of Pancreatic Cancer. J Natl Compr Canc Netw. 2017 May; 15(5S):723-725.
  9. Tempero M. Saying Yes. J Natl Compr Canc Netw. 2017 Mar; 15(3):277.
  10. Tempero M. Mad About MACRA. J Natl Compr Canc Netw. 2017 Feb; 15(2):137.
  11. Tempero M. New Year's Resolutions. J Natl Compr Canc Netw. 2017 Jan; 15(1):1.
  12. Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Brennan L, Feng E, Taguchi I, Janout V, Firpo MA, Mulvihill SJ, Katz MH, Hanash SM. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 Apr; 109(4).
  13. van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. Assessing Researcher Needs for a Virtual Biobank. Biopreserv Biobank. 2017 Jun; 15(3):203-210.
  14. Tempero M. An Oncologist's Letter to Santa. J Natl Compr Canc Netw. 2016 Dec; 14(12):1491.
  15. Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Grützmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA, Hofmann O, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Gill AJ, Pearson JV, Grimmond SM, Waddell N, Biankin AV. Hypermutation In Pancreatic Cancer. Gastroenterology. 2017 Jan; 152(1):68-74.e2.
  16. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 Nov; 45(10):1394-1400.
  17. Tempero M. My Knee Hurts! J Natl Compr Canc Netw. 2016 Nov; 14(11):1335.
  18. Tempero M. Crossing the Line. J Natl Compr Canc Netw. 2016 Oct; 14(10):1191.
  19. Tempero M. Hillary and Donald, Our Patients Are Watching. J Natl Compr Canc Netw. 2016 Sep; 14(9):1047.
  20. Tempero M. I'll Have Another Shot, Please! J Natl Compr Canc Netw. 2016 Aug; 14(8):929.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.